
Eli Lilly COVID-19 drug combo cuts risk of hospitalizations, deaths by 87%: study
Fox News
A combination of two Eli Lilly antibody drugs cut the risk of COVID-19-related hospitalizations and deaths by 87%, the company announced Wednesday, further upholding dosing already authorized by the Food and Drug Administration.
The company noted four deaths, which were all associated with COVID-19 and all occurred in the placebo group. Lilly said the new findings were consistent with other data previously announced, like a cohort involving high-risk patients given 2800 mg of bamlanivimab and 2800 mg of etesevimab, resulting in a 70% reduction in risk of hospitalization and death.More Related News

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












